Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 3Thoracic 1Lymphoid 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Hodgkin Disease 47Lymphoma 22Lymphoma, Non-Hodgkin 18Lymphoma, Large B-Cell, Diffuse 15Multiple Myeloma 12Melanoma 9Lymphoma, B-Cell 9Leukemia, Lymphocytic, Chronic, B-Cell 9Hematologic Neoplasms 9Lymphoma, Follicular 7Myelodysplastic Syndromes 5Mycosis Fungoides 5Lymphoma, T-Cell, Peripheral 5Lymphoma, T-Cell 5Lymphoma, Large-Cell, Anaplastic 5Carcinoma, Renal Cell 5Burkitt Lymphoma 5Uterine Cervical Neoplasms 4Recurrence 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Neoplasm Metastasis 4Lymphoma, T-Cell, Cutaneous 4Lymphoma, B-Cell, Marginal Zone 4Colorectal Neoplasms 4Carcinoma, Merkel Cell 4Breast Neoplasms 4Stomach Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Small Cell Lung Carcinoma 3Pancreatic Neoplasms 3

Interventions

pembrolizumab 2durvalumab 1atezolizumab 1advexin 1Nivolumab 1Injections, Subcutaneous 1Gemcitabine 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms, Squamous Cell × Nivolumab × Lymphoid × Clear all
NCT03544723 2020-06-09

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.

MultiVir, Inc.

Phase 2 Unknown
40 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicLymphoidThoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Hodgkin Disease, Liver Neoplasms, Lymphoma, Melanoma, Stomach Neoplasms, Carcinoma, Merkel Cell, Neoplasms, Squamous Cell, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡